APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liposomal Doxorubicin

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

Selected research

Industry Growth & Trends

Global Liposomal Doxorubicin Industry Growth and Trends Forecast to 2032

26 December 202596 pages

Choose your research edition.

Industry ResearchLiposomal Doxorubicin Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposomal Doxorubicin Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Liposomal Doxorubicin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposomal Doxorubicin Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposomal Doxorubicin Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

Market competition is intense. Johnson & Johnson, Sun Pharmaceutical, CSPC, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 3 accounted for 60.41% market share.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Liposomal Doxorubicin market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Liposomal Doxorubicin market size, estimates, and forecasts are presented in terms of sales volume (K Unit) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Liposomal Doxorubicin market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Liposomal Doxorubicin.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Liposomal Doxorubicin market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Liposomal Doxorubicin Market by Company

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Liposomal Doxorubicin Segment by Type

5 ml

10 ml

25 ml

Liposomal Doxorubicin Segment by Application

Breast Cancer

Liver Cancer

Kidney Cancer

Multiple Myeloma

Ovarian Cancer

Other

Liposomal Doxorubicin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal Doxorubicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposomal Doxorubicin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal Doxorubicin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Liposomal Doxorubicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 5 ml Table 2. Major Company of 10 ml Table 3. Major Company of 25 ml Table 4. Global Liposomal Doxorubicin Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Liposomal Doxorubicin Sales by Type (2021-2026) & (K Unit) Table 6. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2021-2026) Table 7. Global Liposomal Doxorubicin Sales by Type (2021-2026) & (US$ Million) Table 8. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2021-2026) Table 9. Global Liposomal Doxorubicin Price by Type (2021-2026) & (USD/Unit) Table 10. Global Liposomal Doxorubicin Sales by Type (2027-2032) & (K Unit) Table 11. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2027-2032) Table 12. Global Liposomal Doxorubicin Sales by Type (2027-2032) & (US$ Million) Table 13. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2027-2032) Table 14. Global Liposomal Doxorubicin Price by Type (2027-2032) & (USD/Unit) Table 15. North America Liposomal Doxorubicin Sales by Type (2021-2026) & (K Unit) Table 16. North America Liposomal Doxorubicin Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Liposomal Doxorubicin Sales by Type (2021-2026) & (K Unit) Table 18. Europe Liposomal Doxorubicin Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Liposomal Doxorubicin Sales by Type (2021-2026) & (K Unit) Table 20. Asia-Pacific Liposomal Doxorubicin Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Liposomal Doxorubicin Sales by Type (2021-2026) & (K Unit) Table 22. Latin America Liposomal Doxorubicin Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Liposomal Doxorubicin Sales by Type (2021-2026) & (K Unit) Table 24. Middle East and Africa Liposomal Doxorubicin Sales by Type (2021-2026) & (US$ Million) Table 25. Liposomal Doxorubicin Industry Trends Table 26. Liposomal Doxorubicin Industry Drivers Table 27. Liposomal Doxorubicin Industry Opportunities and Challenges Table 28. Liposomal Doxorubicin Industry Restraints Table 29. Global Liposomal Doxorubicin Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Liposomal Doxorubicin Revenue Market Share by Company (2021-2026) Table 31. Global Liposomal Doxorubicin Sales by Company (2021-2026) & (K Unit) Table 32. Global Liposomal Doxorubicin Sales Share by Company (2021-2026) Table 33. Global Liposomal Doxorubicin Market Price by Company (2021-2026) & (USD/Unit) Table 34. Global Liposomal Doxorubicin Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Liposomal Doxorubicin Major Company Production Sites and Headquarters Table 36. Global Liposomal Doxorubicin Company, Product Type & Application Table 37. Global Liposomal Doxorubicin Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Liposomal Doxorubicin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Liposomal Doxorubicin Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Liposomal Doxorubicin Sales by Region (2021-2026) & (K Unit) Table 42. Global Liposomal Doxorubicin Sales Market Share in Volume by Region (2021-2026) Table 43. Global Liposomal Doxorubicin Sales by Region (2021-2026) & (US$ Million) Table 44. Global Liposomal Doxorubicin Sales Market Share in Value by Region (2021-2026) Table 45. Global Liposomal Doxorubicin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 46. Global Liposomal Doxorubicin Sales by Region (2027-2032) & (K Unit) Table 47. Global Liposomal Doxorubicin Sales Market Share in Volume by Region (2027-2032) Table 48. Global Liposomal Doxorubicin Sales by Region (2027-2032) & (US$ Million) Table 49. Global Liposomal Doxorubicin Sales Market Share in Value by Region (2027-2032) Table 50. Global Liposomal Doxorubicin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 51. Global Liposomal Doxorubicin Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Liposomal Doxorubicin Sales by Application (2021-2026) & (K Unit) Table 53. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2021-2026) Table 54. Global Liposomal Doxorubicin Sales by Application (2021-2026) & (US$ Million) Table 55. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2021-2026) Table 56. Global Liposomal Doxorubicin Price by Application (2021-2026) & (USD/Unit) Table 57. Global Liposomal Doxorubicin Sales by Application (2027-2032) & (K Unit) Table 58. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2027-2032) Table 59. Global Liposomal Doxorubicin Sales by Application (2027-2032) & (US$ Million) Table 60. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2027-2032) Table 61. Global Liposomal Doxorubicin Price by Application (2027-2032) & (USD/Unit) Table 62. North America Liposomal Doxorubicin Sales by Application (2021-2026) & (K Unit) Table 63. North America Liposomal Doxorubicin Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Liposomal Doxorubicin Sales by Application (2021-2026) & (K Unit) Table 65. Europe Liposomal Doxorubicin Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Liposomal Doxorubicin Sales by Application (2021-2026) & (K Unit) Table 67. Asia-Pacific Liposomal Doxorubicin Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Liposomal Doxorubicin Sales by Application (2021-2026) & (K Unit) Table 69. Latin America Liposomal Doxorubicin Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Liposomal Doxorubicin Sales by Application (2021-2026) & (K Unit) Table 71. Middle East and Africa Liposomal Doxorubicin Sales by Application (2021-2026) & (US$ Million) Table 72. Johnson & Johnson Company Information Table 73. Johnson & Johnson Business Overview Table 74. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 75. Johnson & Johnson Liposomal Doxorubicin Product Portfolio Table 76. Johnson & Johnson Recent Development Table 77. Sun Pharmaceutical Company Information Table 78. Sun Pharmaceutical Business Overview Table 79. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 80. Sun Pharmaceutical Liposomal Doxorubicin Product Portfolio Table 81. Sun Pharmaceutical Recent Development Table 82. CSPC Company Information Table 83. CSPC Business Overview Table 84. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 85. CSPC Liposomal Doxorubicin Product Portfolio Table 86. CSPC Recent Development Table 87. Kinyond Company Information Table 88. Kinyond Business Overview Table 89. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Kinyond Liposomal Doxorubicin Product Portfolio Table 91. Kinyond Recent Development Table 92. Teva Company Information Table 93. Teva Business Overview Table 94. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Teva Liposomal Doxorubicin Product Portfolio Table 96. Teva Recent Development Table 97. Fudan-Zhangjiang Company Information Table 98. Fudan-Zhangjiang Business Overview Table 99. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Fudan-Zhangjiang Liposomal Doxorubicin Product Portfolio Table 101. Fudan-Zhangjiang Recent Development Table 102. Zydus Cadila Company Information Table 103. Zydus Cadila Business Overview Table 104. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Zydus Cadila Liposomal Doxorubicin Product Portfolio Table 106. Zydus Cadila Recent Development Table 107. TTY Biopharma Company Information Table 108. TTY Biopharma Business Overview Table 109. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. TTY Biopharma Liposomal Doxorubicin Product Portfolio Table 111. TTY Biopharma Recent Development Table 112. North America Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 113. North America Liposomal Doxorubicin Sales by Country (2021-2026) & (K Unit) Table 114. North America Liposomal Doxorubicin Sales Market Share by Country (2021-2026) Table 115. North America Liposomal Doxorubicin Sales Forecast by Country (2027-2032) & (K Unit) Table 116. North America Liposomal Doxorubicin Sales Market Share Forecast by Country (2027-2032) Table 117. North America Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. North America Liposomal Doxorubicin Market Size by Country (2021-2026) & (US$ Million) Table 119. North America Liposomal Doxorubicin Market Share by Country (2021-2026) Table 120. North America Liposomal Doxorubicin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. North America Liposomal Doxorubicin Market Share Forecast by Country (2027-2032) Table 122. Europe Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 123. Europe Liposomal Doxorubicin Sales by Country (2021-2026) & (K Unit) Table 124. Europe Liposomal Doxorubicin Sales Market Share by Country (2021-2026) Table 125. Europe Liposomal Doxorubicin Sales Forecast by Country (2027-2032) & (K Unit) Table 126. Europe Liposomal Doxorubicin Sales Market Share Forecast by Country (2027-2032) Table 127. Europe Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Europe Liposomal Doxorubicin Market Size by Country (2021-2026) & (US$ Million) Table 129. Europe Liposomal Doxorubicin Market Share by Country (2021-2026) Table 130. Europe Liposomal Doxorubicin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Europe Liposomal Doxorubicin Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Liposomal Doxorubicin Sales by Country (2021-2026) & (K Unit) Table 134. Asia-Pacific Liposomal Doxorubicin Sales Market Share by Country (2021-2026) Table 135. Asia-Pacific Liposomal Doxorubicin Sales Forecast by Country (2027-2032) & (K Unit) Table 136. Asia-Pacific Liposomal Doxorubicin Sales Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Liposomal Doxorubicin Market Size by Country (2021-2026) & (US$ Million) Table 139. Asia-Pacific Liposomal Doxorubicin Market Share by Country (2021-2026) Table 140. Asia-Pacific Liposomal Doxorubicin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Asia-Pacific Liposomal Doxorubicin Market Share Forecast by Country (2027-2032) Table 142. Latin America Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 143. Latin America Liposomal Doxorubicin Sales by Country (2021-2026) & (K Unit) Table 144. Latin America Liposomal Doxorubicin Sales Market Share by Country (2021-2026) Table 145. Latin America Liposomal Doxorubicin Sales Forecast by Country (2027-2032) & (K Unit) Table 146. Latin America Liposomal Doxorubicin Sales Market Share Forecast by Country (2027-2032) Table 147. Latin America Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Latin America Liposomal Doxorubicin Market Size by Country (2021-2026) & (US$ Million) Table 149. Latin America Liposomal Doxorubicin Market Share by Country (2021-2026) Table 150. Latin America Liposomal Doxorubicin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Latin America Liposomal Doxorubicin Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Liposomal Doxorubicin Sales by Country (2021-2026) & (K Unit) Table 154. Middle East and Africa Liposomal Doxorubicin Sales Market Share by Country (2021-2026) Table 155. Middle East and Africa Liposomal Doxorubicin Sales Forecast by Country (2027-2032) & (K Unit) Table 156. Middle East and Africa Liposomal Doxorubicin Sales Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Liposomal Doxorubicin Market Size by Country (2021-2026) & (US$ Million) Table 159. Middle East and Africa Liposomal Doxorubicin Market Share by Country (2021-2026) Table 160. Middle East and Africa Liposomal Doxorubicin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Middle East and Africa Liposomal Doxorubicin Market Share Forecast by Country (2027-2032) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Liposomal Doxorubicin Distributors List Table 165. Liposomal Doxorubicin Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. Liposomal Doxorubicin Image Figure 2. Global Liposomal Doxorubicin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposomal Doxorubicin Market Size (2021-2032) & (US$ Million) Figure 4. Global Liposomal Doxorubicin Sales (2021-2032) & (K Unit) Figure 5. 5 ml Image Figure 6. Global 5 ml Sales YoY Growth (2021-2032) & (K Unit) Figure 7. 10 ml Image Figure 8. Global 10 ml Sales YoY Growth (2021-2032) & (K Unit) Figure 9. 25 ml Image Figure 10. Global 25 ml Sales YoY Growth (2021-2032) & (K Unit) Figure 11. Global Liposomal Doxorubicin Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Liposomal Doxorubicin Market Share by Type 2025 VS 2032 Figure 13. North America Liposomal Doxorubicin Sales Market Share in Volume by Type in 2025 Figure 14. North America Liposomal Doxorubicin Sales Market Share in Value by Type in 2025 Figure 15. Europe Liposomal Doxorubicin Sales Market Share in Volume by Type in 2025 Figure 16. Europe Liposomal Doxorubicin Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Liposomal Doxorubicin Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Liposomal Doxorubicin Sales Market Share in Value by Type in 2025 Figure 19. Latin America Liposomal Doxorubicin Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Liposomal Doxorubicin Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Liposomal Doxorubicin Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Liposomal Doxorubicin Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Liposomal Doxorubicin Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Breast Cancer Image Figure 26. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Unit) Figure 27. Liver Cancer Image Figure 28. Global Liver Cancer Sales YoY Growth (2021-2032) & (K Unit) Figure 29. Kidney Cancer Image Figure 30. Global Kidney Cancer Sales YoY Growth (2021-2032) & (K Unit) Figure 31. Multiple Myeloma Image Figure 32. Global Multiple Myeloma Sales YoY Growth (2021-2032) & (K Unit) Figure 33. Ovarian Cancer Image Figure 34. Global Ovarian Cancer Sales YoY Growth (2021-2032) & (K Unit) Figure 35. Other Image Figure 36. Global Other Sales YoY Growth (2021-2032) & (K Unit) Figure 37. Global Liposomal Doxorubicin Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Liposomal Doxorubicin Market Share by Application 2025 VS 2032 Figure 39. North America Liposomal Doxorubicin Sales Market Share in Volume by Application in 2025 Figure 40. North America Liposomal Doxorubicin Sales Market Share in Value by Application in 2025 Figure 41. Europe Liposomal Doxorubicin Sales Market Share in Volume by Application in 2025 Figure 42. Europe Liposomal Doxorubicin Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Liposomal Doxorubicin Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Liposomal Doxorubicin Sales Market Share in Value by Application in 2025 Figure 45. Latin America Liposomal Doxorubicin Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Liposomal Doxorubicin Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Liposomal Doxorubicin Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Liposomal Doxorubicin Sales Market Share in Value by Application in 2025 Figure 49. North America Liposomal Doxorubicin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 50. North America Liposomal Doxorubicin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Liposomal Doxorubicin Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Liposomal Doxorubicin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 54. Europe Liposomal Doxorubicin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Liposomal Doxorubicin Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Liposomal Doxorubicin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 58. Asia-Pacific Liposomal Doxorubicin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Liposomal Doxorubicin Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Liposomal Doxorubicin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 62. Latin America Liposomal Doxorubicin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Liposomal Doxorubicin Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Liposomal Doxorubicin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 66. Middle East and Africa Liposomal Doxorubicin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Liposomal Doxorubicin Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Liposomal Doxorubicin Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Liposomal Doxorubicin Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • 5 ml
  • 10 ml
  • 25 ml
Applications
  • Breast Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Other
Companies covered
  • Johnson & Johnson
  • Sun Pharmaceutical
  • CSPC
  • Kinyond
  • Teva
  • Fudan-Zhangjiang
  • Zydus Cadila
  • TTY Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liposomal Doxorubicin Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Liposomal Doxorubicin Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Liposomal Doxorubicin Market by Type
  6. 1.3.1 5 ml
  7. 1.3.2 10 ml
  8. 1.3.3 25 ml
  9. 1.4 Global Liposomal Doxorubicin Market Size by Type
  10. 1.4.1 Global Liposomal Doxorubicin Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Liposomal Doxorubicin Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Liposomal Doxorubicin Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Liposomal Doxorubicin Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Liposomal Doxorubicin Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Liposomal Doxorubicin Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Liposomal Doxorubicin Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Liposomal Doxorubicin Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Liposomal Doxorubicin Industry Trends
  2. 2.2 Liposomal Doxorubicin Industry Drivers
  3. 2.3 Liposomal Doxorubicin Industry Opportunities and Challenges
  4. 2.4 Liposomal Doxorubicin Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Liposomal Doxorubicin Revenue (2021-2026)
  2. 3.2 Global Top Players by Liposomal Doxorubicin Sales (2021-2026)
  3. 3.3 Global Top Players by Liposomal Doxorubicin Price (2021-2026)
  4. 3.4 Global Liposomal Doxorubicin Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Liposomal Doxorubicin Major Company Production Sites & Headquarters
  6. 3.6 Global Liposomal Doxorubicin Company, Product Type & Application
  7. 3.7 Global Liposomal Doxorubicin Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Liposomal Doxorubicin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Liposomal Doxorubicin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Liposomal Doxorubicin Tier 1, Tier 2, and Tier 3
4 Liposomal Doxorubicin Regional Status and Outlook
  1. 4.1 Global Liposomal Doxorubicin Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Liposomal Doxorubicin Historic Market Size by Region
  3. 4.2.1 Global Liposomal Doxorubicin Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Liposomal Doxorubicin Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Liposomal Doxorubicin Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Liposomal Doxorubicin Forecasted Market Size by Region
  7. 4.3.1 Global Liposomal Doxorubicin Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Liposomal Doxorubicin Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Liposomal Doxorubicin Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Liposomal Doxorubicin by Application
  1. 5.1 Liposomal Doxorubicin Market by Application
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Liver Cancer
  4. 5.1.3 Kidney Cancer
  5. 5.1.4 Multiple Myeloma
  6. 5.1.5 Ovarian Cancer
  7. 5.1.6 Other
  8. 5.2 Global Liposomal Doxorubicin Market Size by Application
  9. 5.2.1 Global Liposomal Doxorubicin Market Size Overview by Application (2021-2032)
  10. 5.2.2 Global Liposomal Doxorubicin Historic Market Size Review by Application (2021-2026)
  11. 5.2.3 Global Liposomal Doxorubicin Forecasted Market Size by Application (2027-2032)
  12. 5.3 Key Regions Market Size by Application
  13. 5.3.1 North America Liposomal Doxorubicin Sales Breakdown by Application (2021-2026)
  14. 5.3.2 Europe Liposomal Doxorubicin Sales Breakdown by Application (2021-2026)
  15. 5.3.3 Asia-Pacific Liposomal Doxorubicin Sales Breakdown by Application (2021-2026)
  16. 5.3.4 South America Liposomal Doxorubicin Sales Breakdown by Application (2021-2026)
  17. 5.3.5 Middle East and Africa Liposomal Doxorubicin Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Liposomal Doxorubicin Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Sun Pharmaceutical
  8. 6.2.1 Sun Pharmaceutical Company Information
  9. 6.2.2 Sun Pharmaceutical Business Overview
  10. 6.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Portfolio
  12. 6.2.5 Sun Pharmaceutical Recent Developments
  13. 6.3 CSPC
  14. 6.3.1 CSPC Company Information
  15. 6.3.2 CSPC Business Overview
  16. 6.3.3 CSPC Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 CSPC Liposomal Doxorubicin Product Portfolio
  18. 6.3.5 CSPC Recent Developments
  19. 6.4 Kinyond
  20. 6.4.1 Kinyond Company Information
  21. 6.4.2 Kinyond Business Overview
  22. 6.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Kinyond Liposomal Doxorubicin Product Portfolio
  24. 6.4.5 Kinyond Recent Developments
  25. 6.5 Teva
  26. 6.5.1 Teva Company Information
  27. 6.5.2 Teva Business Overview
  28. 6.5.3 Teva Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Teva Liposomal Doxorubicin Product Portfolio
  30. 6.5.5 Teva Recent Developments
  31. 6.6 Fudan-Zhangjiang
  32. 6.6.1 Fudan-Zhangjiang Company Information
  33. 6.6.2 Fudan-Zhangjiang Business Overview
  34. 6.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Portfolio
  36. 6.6.5 Fudan-Zhangjiang Recent Developments
  37. 6.7 Zydus Cadila
  38. 6.7.1 Zydus Cadila Company Information
  39. 6.7.2 Zydus Cadila Business Overview
  40. 6.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Zydus Cadila Liposomal Doxorubicin Product Portfolio
  42. 6.7.5 Zydus Cadila Recent Developments
  43. 6.8 TTY Biopharma
  44. 6.8.1 TTY Biopharma Company Information
  45. 6.8.2 TTY Biopharma Business Overview
  46. 6.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 TTY Biopharma Liposomal Doxorubicin Product Portfolio
  48. 6.8.5 TTY Biopharma Recent Developments
7 North America by Country
  1. 7.1 North America Liposomal Doxorubicin Sales by Country
  2. 7.1.1 North America Liposomal Doxorubicin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Liposomal Doxorubicin Sales by Country (2021-2026)
  4. 7.1.3 North America Liposomal Doxorubicin Sales Forecast by Country (2027-2032)
  5. 7.2 North America Liposomal Doxorubicin Market Size by Country
  6. 7.2.1 North America Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Liposomal Doxorubicin Market Size by Country (2021-2026)
  8. 7.2.3 North America Liposomal Doxorubicin Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Liposomal Doxorubicin Sales by Country
  2. 8.1.1 Europe Liposomal Doxorubicin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Liposomal Doxorubicin Sales by Country (2021-2026)
  4. 8.1.3 Europe Liposomal Doxorubicin Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Liposomal Doxorubicin Market Size by Country
  6. 8.2.1 Europe Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Liposomal Doxorubicin Market Size by Country (2021-2026)
  8. 8.2.3 Europe Liposomal Doxorubicin Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Liposomal Doxorubicin Sales by Country
  2. 9.1.1 Asia-Pacific Liposomal Doxorubicin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Liposomal Doxorubicin Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Liposomal Doxorubicin Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Liposomal Doxorubicin Market Size by Country
  6. 9.2.1 Asia-Pacific Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Liposomal Doxorubicin Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Liposomal Doxorubicin Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Liposomal Doxorubicin Sales by Country
  2. 10.1.1 South America Liposomal Doxorubicin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Liposomal Doxorubicin Sales by Country (2021-2026)
  4. 10.1.3 South America Liposomal Doxorubicin Sales Forecast by Country (2027-2032)
  5. 10.2 South America Liposomal Doxorubicin Market Size by Country
  6. 10.2.1 South America Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Liposomal Doxorubicin Market Size by Country (2021-2026)
  8. 10.2.3 South America Liposomal Doxorubicin Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Liposomal Doxorubicin Sales by Country
  2. 11.1.1 Middle East and Africa Liposomal Doxorubicin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Liposomal Doxorubicin Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Liposomal Doxorubicin Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Liposomal Doxorubicin Market Size by Country
  6. 11.2.1 Middle East and Africa Liposomal Doxorubicin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Liposomal Doxorubicin Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Liposomal Doxorubicin Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Liposomal Doxorubicin Value Chain Analysis
  2. 12.1.1 Liposomal Doxorubicin Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Liposomal Doxorubicin Production Mode & Process
  7. 12.2 Liposomal Doxorubicin Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Liposomal Doxorubicin Distributors
  10. 12.2.3 Liposomal Doxorubicin Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst